Equities research analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS - Get Free Report) in a research note issued on Monday. The brokerage set a "sell" rating on the biotechnology company's stock.
Separately, Barclays dropped their target price on Cellectis from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Tuesday, November 5th.
Get Our Latest Analysis on CLLS
Cellectis Stock Down 4.2 %
Shares of NASDAQ:CLLS traded down $0.07 during trading on Monday, reaching $1.57. 19,875 shares of the stock were exchanged, compared to its average volume of 51,332. The stock has a fifty day moving average of $1.88 and a two-hundred day moving average of $2.06. Cellectis has a 1-year low of $1.53 and a 1-year high of $3.55. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market cap of $87.37 million, a price-to-earnings ratio of -1.21 and a beta of 3.09.
Cellectis (NASDAQ:CLLS - Get Free Report) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same period in the previous year, the firm earned ($0.31) earnings per share. Research analysts anticipate that Cellectis will post -0.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cellectis
Several hedge funds have recently modified their holdings of CLLS. First Affirmative Financial Network purchased a new stake in shares of Cellectis during the 3rd quarter valued at $45,000. Long Focus Capital Management LLC grew its position in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after buying an additional 130,000 shares during the period. XTX Topco Ltd purchased a new stake in Cellectis during the second quarter worth about $29,000. Finally, Principal Financial Group Inc. raised its position in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock worth $817,000 after acquiring an additional 12,467 shares during the period. Institutional investors own 63.90% of the company's stock.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Recommended Stories
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
